BRAF and lung carcinoma: However, in the prospective lung cancer genomic screening project (LC-SCRUM-Asia) enrolling 380 BRAF-mutated NSCLC (119 class I, 122 class II and 86 class III), PFS in response to platinum-containing chemotherapies (5.3 vs. 11.5 months, p < 0.01) and OS (14.5 vs. 34.8 months, p < 0.02) was significantly shorter in patients with class III as compared with class I [25].